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ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is usually characterized by uncontrolled
complement activation. The recent discovery of loss-of-functionmutations inDGKE
in patients with aHUS and normal complement levels challenged this observation.
DGKE, encoding diacylglycerol kinase-«, has not been implicated in the complement
cascade but hypothetically leads to a prothrombotic state. The discovery of this
novel mechanism has potential implications for the treatment of infants with aHUS,
who are increasingly treated with complement blocking agents. In this study, we
used homozygosity mapping and whole-exome sequencing to identify a novel trun-
cating mutation in DGKE (p.K101X) in a consanguineous family with patients af-
fected by thrombotic microangiopathy characterized by significant serum
complement activation and consumption of the complement fraction C3. Aggres-
sive plasma infusion therapy controlled systemic symptoms and prevented renal
failure, suggesting that this treatment can significantly affect the natural history of
this aggressive disease. Our study expands the clinical phenotypes associated with
mutations inDGKE and challenges the benefits of complement blockade treatment
in such patients. Mechanistic studies of DGKE and aHUS are, therefore, essential to
the design of appropriate therapeutic strategies in patients with DGKE mutations.
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Hemolytic uremic syndrome (HUS) is
characterized by thrombosis of the small
vessels, resulting in microangiopathic he-
molytic anemia, renal failure, and throm-
bocytopenia.1 In contrast to classical
HUS, which is secondary to infection
with specific Escherichia coli serotypes,
atypical HUS (aHUS) is caused by genetic
or autoimmune factors involved in the
complement system.2 Up to 65% of pa-
tients progress to ESRD or die within 1
year after diagnosis.3 Most identified
disease-causing mutations in aHUS affect
genes encoding complement factors, such
as CFH, CFB and CFI, and C3 and MCP,
leading to uncontrolled activation of the
complement cascade at the cell surface
level.2 Consequently, treatment aimed to
block complement cascade activation has
been proven effective.4
Recently, two studies independently
identified mutations in DGKE (Online
Mendelian Inheritance in Man 15008),
encoding diacylglycerol kinase-«, in
families with aHUS andmembranoprolif-
erativeGN.5,6 The patients in these studies
did not show abnormal complement lev-
els, suggesting that DGKE does not play a
role in complement activation but
causes a thrombotic phenotype by influ-
encing endothelial cells and platelets func-
tion.7 The absence of overt complement
activation in such patients suggested that
treatment with complement inhibitors,
such as eculizumab, would be ineffica-
cious. In this study, we expand the clinical
phenotype of DGKE-associated diseases
to hypocomplementemic aHUS.
Westudied a family spanningmultiple
generations with at least four recognized
loops of consanguinity (Figure 1). The
family originates from Linosa, a remote
island in the Mediterranean Sea that is
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inhabited by about 450 persons and
characterized by a high rate of endog-
amy. There were four individuals (45,
58, 59, and 61) affected by thrombotic
microangiopathy and three individuals
with an unknown phenotype (46, 47,
and 62). Individual 45 was reported by
history to have had thrombotic micro-
angiopathy with heavy proteinuria at
young age and died in childhood. Indi-
vidual 61 was diagnosed with biopsy-
proven aHUS after an episode of acute
hemolytic anemia and renal failure after
corrective surgery for congenital cataract
in 2000 at the age of 1 year. The patient
died at the age of 15 months. Individual
47 died in childhood from an unclear
illness; individual 62 was subjected to
corrective surgery for congenital cataract
at the age of 6months at Gaslini Hospital
in 2003. He was found to have high lac-
tate dehydrogenase (579 U/L), low hap-
toglobin (3 mg/dl), and low serum C3
(69 mg/dl), but because renal function
was normal and there was no anemia or
proteinuria, he was not subjected to
treatment. Four individuals (50, 51, 58,
and 59) were available for this study.
The index patient (individual 58)
presented at 10 months of age with acute
renal failure, proteinuria, hematuria,
elevated lactate dehydrogenase, low hap-
toglobin levels, and low platelets (Table
1). Serum complement C3 was 66 mg/dl
(normal values=84–192 mg/dl),
suggesting a clinical diagnosis of HUS.
Serum complement C4 was within nor-
mal range (15mg/dl; normal values=10–
42mg/dl). Plasma infusionwas started at
10 ml/kg per day for 2 weeks with im-
provement of clinical symptoms and
laboratory abnormalities (C3 levels
increased to 111 mg/dl). Renal biopsy,
performed 3 months after presentation
because of persistent proteinuria, was
consistent with the diagnosis of subacute
HUS (Figure 2).
Plasma infusion was conducted every
month in the first 1 year after diagnosis
and continued every 3months afterward.
Interestingly, despite transitory im-
provement with plasma infusions, C3
levels remained low during follow-up
(Figure 3A). Renal function recovered
shortly after diagnosis, but proteinuria
and microhematuria persisted during
follow-up (Table 1). At 5 years of age,
she has normal renal function and is
treated daily with a combination of an
angiotensin-converting enzyme inhibi-
tor and an angiotensin receptor blocker
for proteinuria and every 3 months with
plasma infusion.
The younger brother (individual 59)
of the indexpatient developedacute renal
failure, proteinuria, hemolysis, increased
BP, and low platelet count at the age of 8
months after an exanthematous viral
infection (sixth disease). Serum comple-
ment C3 level was at the lower limit of
the normal range (86 mg/dl; normal
values=84–192 mg/dl). Serum C4 was
within normal range. Because of the
similarity in clinical presentation with
his older sibling, plasma infusion was
initiated. Similar to his sibling, C3 re-
mained below the normal level during
follow-up (Figure 3B, Table 1). At 3 years
of age, renal function is still normal, pro-
teinuria is absent, and there is persistent
microhematuria. The patient remains
dependent on plasma infusion (per-
formed every 3 months), and he is not
on pharmacological treatment during
the plasma-free intervals. The absence of
proteinuria at follow-up in patient 59 sug-
gests that early aggressive and continuous
treatment with plasma infusion can sig-
nificantly change the natural history of
disease and prevent podocyte damage in
patients with DGKE mutations. Both pa-
rents are healthy, with no evidence of
hemolysis or significant complement con-
sumption at repeated laboratory tests. The
average C3 complement fraction level,
measured using the same assay, in 426
children without overt immunologic dis-
eases was 114.1 mg/dl (median, 110.5;
95% confidence interval, 111.9 to 116.3).
Homozygosity mapping identified six
regions across the genome (Figure 4A)
that were homozygous in individual 58
and heterozygous in her parents (50 and
51). These regions collectively spanned
64.7 Mb (approximately 2.3% of the ge-
nome, including 658 transcriptional
units) (Supplemental Table 1). Exome
sequencing performed on individual 58
resulted in an average depth of 51.5X,
with 95.51% of bases covered at a depth
of 4X or higher. We identified 38,119
Figure 1. Structure of the pedigree analyzed in the current study. Square symbols repre-
sent men, and circles represent women. Consanguineous unions are represented by double
horizontal lines. Black-filled symbols represent affected individuals, white symbols repre-
sent unaffected individuals, and gray-filled symbols represent phenotype unknown. Black-
filled dot superscript represents DGKE mutation in homozygous state; black open dot
superscript represents DGKE mutation carriers (heterozygous state).
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unique single nucleotide variants
(SNVs) (Figure 4B). Of these SNVs,
764 (500 SNVs and 264 indels) SNVs
were of high quality and absent from
the Single Nucleotide Polymorphism
Database, 1000 Genome, and National
Heart, Lung, and Blood Institute Exome
Variant Server databases. Among those
SNVs, 194 (169 SNVs and 24 indels)
SNVs were protein-altering variants
(truncating,missense, or predicted to af-
fect splicing), and only 3 SNVs were
present in homozygous state. Two var-
iants (a deletion of an A 2 bp upstream
of exon 4 of PRB3 and a missense
p.D2115V in MUC4) were not under
any of the homozygosity peaks but they
present at high frequency in 45 exomes
from IgA nephropathy patients available
in the laboratory that were processed at
the same time as our patients. The third
variant, a homozygous mutation c.301
A.T, resulted in a premature termina-
tion at the aminoacidic position 101
(p.K101X) inDGKE.This gene is located
within the distal 290 kb of the region of
homozygosity on chromosome 17q21–
22. Sanger sequencing confirmed that
individuals 58 and 59 were homozygous
for the p.K101X mutation and that their
parents, 50 and 51, were heterozygous
for this variant (Figure 4C). Linkage
analysis using an autosomal recessive
model using the p.K101X mutation as a
marker8 resulted in an logarithm of odds
score of 2.4 at theDGKE locus, supporting
gene localization for this family. Finally,
this variant, absent in .6500 publicly
available controls, was absent in an addi-
tional 118 ethnically and geographically
matched controls. DGKE mutations were
recently associated to noncomplement-
mediated forms of aHUS and mem-
branoproliferative GN,5,6 suggesting that
this form of hypocomplementemic
thrombotic microangiopathy is allelic to
the forms previously reported.
Because of the significantly different
serologic phenotype inour patients com-
pared with the recently reported patients
with DGKE mutations, we explored the
possibility that additional functional
variants in genes involved in the innate
immunity might account for the low se-
rum complement.9 No rare homozygous
or heterozygous variants were found in
the genes previously associated with
complement-mediated forms of aHUS,
such as CFH, CFB, CFI, C3, or MCP
and other genes of the complement sys-
tem (Supplemental Table 2), and no
other rare deleterious variants were
found in the regions of homozygosity.
Figure 2. Renal histology studies in individual 58. Representative glomeruli show features
of subacute thrombotic microangiopathy. (A) There is global glomerular endothelial cell swell-
ing and mild hypercellularity producing a picture of endotheliosis. No intracapillary fibrin
thrombi are identified (periodic acid–Schiff, 3400). (B) The same glomerulus in a deeper level
shows irregular thickening and narrow duplication of glomerular basement membranes, which
are segmentally associated with mesangial interposition (periodic acid–Schiff,3400). (C) There
is duplication of many glomerular basement membranes (producing double contours) without
associated mesangial hypercellularity. The podocytes appear swollen (Jones methenamine
silver,3400). (D)Theglomerular capillary luminaare segmentally expandedowing todissolution
of the mesangial matrix, consistent with mesangiolysis. Some of the adjacent glomerular cap-
illary walls appear thickened with duplication of glomerular basement membranes (Masson tri-
chrome,3400). Immunofluorescence revealed glomerular staining for IgM and fibrin/fibrinogen,
with negativity for IgG, IgA, C1q, C3, and C4 (not shown).
Table 1. Clinical characteristics of individuals 58 and 59 at presentation and last
follow-up
Individual 58 (Girl) Individual 59 (Boy)
Presentation Last Follow-Up Presentation Last Follow-Up
Age (yr) 0.8 5.3 0.7 3.4
SCr (mg/dl) 1.5 0.29 11.4 0.30
Platelet count (3109/L) 64 279 30 201
LDH (IU/L) 1923 414 2736 551
Haptoglobin ,2 46 ,2 ,2
C3 (mg/dl) 66 79 86 78
Proteinuria Yes Yes Yes No
Hematuria Yes Yes Yes Yes
Reference values for C3: 84–192 mg/dl. Proteinuria is defined as a protein-to-creatinine ratio greater than
0.2 mg/mg on a morning urine sample. Hematuria is defined as greater than 3 red blood cells/high power
field on urinalysis. SCr, serum creatinine; LDH, lactic dehydrogenase; C3, serum complement C3 level.
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Importantly, all family individuals were
homozygous for the wild-type allele at
the rs6677604 locus, a single nucleotide
polymorphism that is in nearly perfect
linkage disequilibriumwith a deletion of
CFHR3 and CFHR1.10 Deletions of these
genes (and CFHR4) are associated with
production of autoantibodies to com-
plement factor H and can result in low
serum complement.11 Deletion of
CFHR4 was excluded by the presence
of single nucleotide polymorphisms in
the heterozygous state in this gene (Sup-
plemental Table 2). Finally, anti-factor H
autoantibodies were absent in all four
individuals.12 Taken together, these
data strongly implicate the p.K101Xmu-
tation in DGKE as the most likely single
cause of the hypocomplementemic phe-
notype of this form of microangiopathy.
The mechanism by which mutations in
DGKE result in complement activation
is unclear. A possibility is that the effect
of DGKE on protein kinase C activation
would lead to a downregulation of
vascular endothelial growth factor
receptor 2, which in turn, would re-
sult in reduced expression of decay-
accelerating factor and consequent
activation of complement at the en-
dothelial cells surface.13
The advent of next generation se-
quencing boosted gene discovery for
Mendelian diseases and helped in solving
the pathogenesis of numerous familial
and sporadic genetic nephropathies.14–16
Although this technology helped to for-
mulate accurate diagnosis and improve
knowledge in pathophysiological and
therapeutic aspects of many diseases,
there are increasing examples in which
deep resequencing of human genomes
or exomes showed that many genes can
harbor mutations with pleiotropic
phenotypic effect that confounded tra-
d i t iona l gene ident ificat ion ap-
proaches.17,18 In a recent report, Boyer
et al.18 performed whole-exome se-
quencing in families with autosomal
dominant FSGS without extrarenal
manifestations to surprisingly identify
segregating mutations in LMX1B, a
gene implicated in the nail patella syn-
drome.19,20 This phenotypic expansion
suggests that the traditional approaches
to gene identification forMendelian dis-
eases, based on strict partitioning of phe-
notypes before candidate gene or
genome-wide studies, might require a
more agnostic approach to identify
causal deleterious mutations and then
classify diseases based on the underlying
molecular defect.
Here, using homozygosity mapping
coupled to exome sequencing, we
identified a previously unreported ho-
mozygous truncatingmutation inDGKE
in a consanguineous family with a form
of aHUS characterized by hypocomple-
mentemia and dependence from plasma
infusion. The good response to plasma
infusion in our patients together with
the observation that at least one patient
from the study by Lemaire et al.5 had
disease recurrence while on treatment
with eculizumab suggest that aggressive
plasma infusion treatment may signifi-
cantly change the natural history of this
disease.
Our findings expand the phenotypic
spectrum of DGKE-related diseases to
hypocomplementemic aHUS and have
potential implications for treatment.
The availability of genome-wide high-
density genotyping and whole-exome
sequencing allowed us to exclude other
genetic causes of low complement level,
such as deletions of the CFHR1, CFHR3,
and CFHR4 or mutations in other genes
involved in aHUS or complement regu-
lation. Notably, Dgke-null mice did not
show overt renal disease or a thrombotic
phenotype,21 indicating that the exact
role of DGKE mutations in aHUS and
the complement system still remains to
be elucidated.
This family originates from a remote
island in the Mediterranean Sea called
Linosa, which has only 450 inhabitants
and is characterized by a high rate of
endogamy. Linosa is a small (2.1 mi2)
volcanic island located in the Mediterra-
nean Sea 101 miles south of Sicily. The
island has no airport and can be reached
only by boat. The presence of multiple
individuals affected by aHUS in this fam-
ily suggests that the p.K101X mutations
might have a high prevalence on this is-
land. The common environmental expo-
sure, the reduced gene pool, and the high
mutation frequency make this population
ideal to study the natural history of this
disease and design appropriate functional
studies and therapeutic strategies.
CONCISE METHODS
Patients and Families
Patient recruitment was performed at
G. Gaslini Institute in Genoa, Italy, between
2008 and 2011. We collected peripheral blood
samples for DNA isolation from the proband,
her parents, and her brother. The Institu-
tional ReviewBoard for ColumbiaUniversity
and local ethic review committees in Genoa
approved the study protocol.
Figure 3. Longitudinal data on serum complement C3 levels. Individual 58 (A) and in-
dividual 59 (B). Arrows indicate hospital admissions for which there were data on serum
complement C3 levels pre- and postplasma infusions. Treatment with plasma infusions is
shown tomaintain complement levels within normal ranges (84–192mg/dl; gray area) only
for a limited period of time after administration, indicate chronic active complement ac-
tivation and consumption.




Genomic DNA was purified from peripheral
bloodcellsusing standardprocedures.Genome-
wide genotyping was conducted on individuals
50, 51, and 58 using the Omni1-quad chips
(Illumina). Genotype data were processed for
quality controls using PLINK software22 as
previously described.23Homozygositymapping
was performed using theHomozygositymapper
program (http://www.homozygositymapper.
org/) as previously described.14 Whole-exome
Figure 4. Identification of a truncating mutation inDGKE. (A) Genome-wide plot for homozygosity. Red bars indicate areas of significant
homozygosity in individual 58 with heterozygosity in the parents (individuals 50 and 51). The six regions span 64.7Mb and encompass 658
transcriptional units. The localization of the complement genes involved in aHUS are displayed; only DGKE is included under an area of
significant homozygosity. (B) Schematic representation of the filtering pipeline for exome sequencing data that resulted in only one
deleterious homozygous variant included in the chromosome 17 homozygosity region (DGKE p.K101X). (C) Sanger sequencing ofDGKE
p.K101X in individuals 50, 51, 58, and 59 shows the mutation in homozygosity in the affected patients 58 and 59 and the mutation in
heterozygous state in their parents, patients 50 and 51.
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sequencing was performed on individual 58




pubmed; Online Mendelian Inheritance in
Man: http://www.ncbi.nlm.nih.gov/omim;
the Single Nucleotide Polymorphism Data-
base: http://www.ncbi.nlm.nih.gov/SNP;
1000 Genome Project: www.1000genomes.
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